Project description
Biomarker identification for neurodegenerative diseases and brain tumours
Diagnostic biomarkers are crucial for early disease detection and effective management, providing essential information about disease presence, progression and response to treatment. In Alzheimer's disease (AD) and glioblastoma (GBM), there is a significant gap in available biomarkers, making early diagnosis and monitoring challenging. The ERC-funded NanoNeuroOmics project proposes to use nanoparticles to isolate and identify brain disease-specific protein markers from blood. Researchers will profile blood and brain proteomes to uncover early diagnostic biomarkers and explore the molecular links between AD and GBM, focusing on their inverse comorbidity. The identification of overlapping pathways will improve understanding of disease biology and advance personalised treatment and management.
Objective
NanoNeuroOmics ambition is to bring together nanotechnology, proteomics and blood biomarker discovery at the emerging intersection of neurodegeneration and neurooncology. NanoNeuroOmics proposes a nanotechnology-based innovative solution for the integrative profiling of the blood and brain tissue proteomes to address two interconnected challenges: i) The unmet clinical need for early diagnostic and disease-monitoring blood biomarkers for two of the most challenging Central Nervous System disorders, namely Alzheimer’s disease (AD) and Glioblastoma (GBM); and ii) The AD-GBM ‘inverse comorbidity’ knowledge gap and intriguing molecular interrelation. NanoNeuroOmics presents a novel approach, in which nanoparticles are employed as scavenging agents to uncover brain disease-specific protein markers in blood, otherwise buried under the overwhelming signal of highly abundant molecules. NanoNeuroOmics aims to tackle the technological challenge of discovering highly specific blood biomarkers, by longitudinally tracking blood and brain proteomic signals at different stages of disease progression. To leverage its full potential, the proposed research programme combines longitudinal preclinical studies with human patient clinical validation studies. Such multi-dimensional proteomic approaches are expected to pioneer new blood biomarker discoveries and to provide mechanistic insight into the comorbidity of neurological diseases. NanoNeuroOmics attempts to discover a distinct set of dysregulated proteins for each of AD and GBM independently and to unveil overlapping molecular pathways to explain the AD-GBM inverse comorbidity. In a broader context, NanoNeuroOmics aspires to bridge the gap between brain pathophysiology and molecular alterations in the blood, across the biological continuum of disease progression. The project takes on a multidisciplinary approach and builds on breakthroughs in nanotechnology and omics sciences, to advance early detection and stratified medicine.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences neurobiology
- natural sciences biological sciences biochemistry biomolecules proteins proteomics
- medical and health sciences basic medicine neurology dementia alzheimer
- medical and health sciences basic medicine physiology pathophysiology
- engineering and technology nanotechnology nano-materials
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.1.1 - European Research Council (ERC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-ERC - HORIZON ERC Grants
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) ERC-2024-STG
See all projects funded under this callHost institution
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
M13 9PL Manchester
United Kingdom
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.